ArticleInternational journal of pharmaceutics: X2025
Alleviating ulcerative colitis via rectal administration: Enhancing the therapeutic effects of silk sericin-proanthocyanidins nanoparticles with a Poloxamer thermosensitive in situ gel.
Article in International journal of pharmaceutics: X, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Study on Echinacoside-Copper Metal-Phenolic Networks Hydrogel System Loaded with Diallyl Trisulfide for Local Treatment of Cervical Cancer.Pharmaceutics · 2026Article
- In situ forming hydrogels for colorectal cancer therapy.Materials today. Bio · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ulcerative colitis, a type of inflammatory bowel disease, primarily impacts the colon's mucous membrane, leading to distressing symptoms. Both healthcare and socioeconomic aspects are significantly impacted by this condition. In this study, we stabilized proanthocyanidins (PAC) with silk sericin (SS) to create SS/PAC nanoparticles. These nanoparticles were then loaded into a thermosensitive in situ hydrogel made with Poloxamer. The effectiveness and safety of the resulting SS/PAC/P thermosensitive hydrogel were evaluated using a dextran sulfate sodium (DSS)-induced model of ulcerative colitis, through rectal administration of the hydrogel. SS/PAC/P demonstrated excellent compatibility and hemocompatibility. It exhibited strong antioxidant and anti-inflammatory properties, effectively relieving ulcerative colitis by counteracting its adverse effects. It alleviated abnormal disease activity index (DAI) scores, improved colon conditions, enhanced histological characteristics, and regulated microbial homeostasis. The superior effectiveness of SS/PAC/P hydrogel in vivo can be attributed to its prolonged residence time at the targeted site of administration, facilitating the continuous release of SS/PAC from the hydrogel. SS/PAC/P has shown potential as a promising therapeutic intervention for managing ulcerative colitis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.